133 results
Page 4 of 7
8-K
EX-99.2
i77zxk4gbd ex
9 Feb 21
Orchard Therapeutics Announces $150 Million Strategic Financing
7:10am
8-K
EX-10.1
9etvzv2d 861x
9 Feb 21
Orchard Therapeutics Announces $150 Million Strategic Financing
7:10am
8-K
EX-99.1
7wh5rrwit5sjj5rnx1
11 Jan 21
Results of Operations and Financial Condition
7:05am
8-K
EX-99.1
jgmwiv3v0 nqd9
16 Oct 20
Other Events
6:03am
8-K
EX-99.1
73plxflcium mq44vrv7
28 Sep 20
Orchard Therapeutics Receives EMA PRIME Designation for OTL-203 for the Treatment of MPS-I
7:03am
8-K
EX-99.1
lwwb ddgvhify9dnbtnh
1 Sep 20
Orchard Therapeutics Announces Additional Interim Results from Proof-of-Concept Study of OTL-203 for MPS-I
7:03am
S-8
EX-99.2
guf1db ueb
6 Aug 20
Registration of securities for employees
4:07pm
8-K
EX-99.1
hq9sphhyaeb10j nqce
6 Aug 20
Orchard Therapeutics Advances New Strategic Plan and Reports Second Quarter 2020 Financial Results
7:03am
8-K
EX-99.1
e7a8zsmof2w
20 Jul 20
Orchard Therapeutics Announces Orphan Drug and Rare Pediatric Disease Designations for OTL-203 for the Treatment of MPS-I
7:03am
8-K
EX-99.1
sd5y a19wgeyw4znex
9 Jul 20
Orchard Therapeutics and MolMed Announce Extension of Gene Therapy Manufacturing Collaboration
7:03am
8-K
EX-3.1
qj6g0qx
19 Jun 20
Amendments to Articles of Incorporation or Bylaws
4:09pm
10-Q
e05g4eou7kdj
7 May 20
Quarterly report
4:03pm
10-Q
EX-10.1
uutmzx1bp1p05a ijq
7 May 20
Quarterly report
4:03pm
8-K
EX-99.1
v703 ayv1u
7 May 20
Orchard Therapeutics Unveils New Strategic Plan and Reports First Quarter 2020 Financial Results
7:03am
DEF 14A
0fg179sx
29 Apr 20
Definitive proxy
4:02pm
PRE 14A
rb396legeij
14 Apr 20
Preliminary proxy
4:46pm
8-K
EX-10.3
sehqwzhfp291p 89cn4j
20 Mar 20
Orchard Therapeutics Appoints Company Founder and Gene Therapy Pioneer Bobby Gaspar, M.D., Ph.D., as New Chief Executive Officer
4:11pm